Description

Simple

Clinical

Overview

Abetimus was developed by La Jolla Pharmaceuticals as an immunosuppressant but was never marketed in American or Europe despite application for marketing authorization in the mid-2000s.

Pharmacology

Indication

Investigated for use/treatment in kidney disease and systemic lupus erythematosus.

Pharmacodynamic

Information currently not available.

Mechanism of action

Information currently not available.

Absorption

Information currently not available.

Protein binding

Information currently not available.

Volume of distribution

Information currently not available.

Clearance

Information currently not available.

Half life

Information currently not available.

Route of elimination

Information currently not available.

Toxicity

Information currently not available.

Adverse Effects

Contraindications

Information currently not available.

Food Interactions

    Information currently not available.

Interactions

Type in a drug name to check for interaction with Abetimus
Type a drug name in the box above to get started
  • Paracetamol(acetaminophen)
  • Paxil(paroxetine)
  • Pamelor(nortriptyline)
  • Panadol(acetaminophen)
  • Patanol(olopatadine ophthalmic)
  • Pataday(olopatadine ophthalmic)
  • Parnate(tranylcypromine)
  • Pazeo(olopatadine ophthalmic)
2-Methoxyethanol
The risk or severity of adverse effects can be increased when 2-Methoxyethanol is combined with Abetimus.
9-(N-methyl-L-isoleucine)-cyclosporin A
The risk or severity of adverse effects can be increased when Abetimus is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
The risk or severity of adverse effects can be increased when Abatacept is combined with Abetimus.
Acteoside
The risk or severity of adverse effects can be increased when Abetimus is combined with Acteoside.
Adalimumab
The risk or severity of adverse effects can be increased when Adalimumab is combined with Abetimus.
Adenovirus type 7 vaccine live
The risk or severity of infection can be increased when Adenovirus type 7 vaccine live is combined with Abetimus.
Afelimomab
The risk or severity of adverse effects can be increased when Afelimomab is combined with Abetimus.
Aldesleukin
The risk or severity of adverse effects can be increased when Aldesleukin is combined with Abetimus.
Aldosterone
The risk or severity of adverse effects can be increased when Aldosterone is combined with Abetimus.
Alefacept
The risk or severity of adverse effects can be increased when Alefacept is combined with Abetimus.
Alemtuzumab
The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Abetimus.
Altretamine
The risk or severity of adverse effects can be increased when Altretamine is combined with Abetimus.
Amsacrine
The risk or severity of adverse effects can be increased when Amsacrine is combined with Abetimus.
Anakinra
The risk or severity of adverse effects can be increased when Anakinra is combined with Abetimus.
Anthrax immune globulin human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Abetimus.
Anthrax vaccine
The risk or severity of infection can be increased when Anthrax vaccine is combined with Abetimus.
Antilymphocyte immunoglobulin (horse)
The risk or severity of adverse effects can be increased when Abetimus is combined with Antilymphocyte immunoglobulin (horse).
Antithymocyte immunoglobulin (rabbit)
The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Abetimus.
Apremilast
The risk or severity of adverse effects can be increased when Apremilast is combined with Abetimus.
Arsenic trioxide
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Abetimus.
2 References
  1. 1 . Authors unspecified: Abetimus: Abetimus sodium, LJP 394. BioDrugs. 2003;17(3):212-5.PubMed: 12749759
  2. 2 . Wallace DJ: Clinical and pharmacological experience with LJP-394. Expert Opin Investig Drugs. 2001 Jan;10(1):111-7.PubMed: 11116284